4-(4-氯-3-硝基苯磺酰基)-吗啉 | 22179-31-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(4-氯-3-硝基苯磺酰基)-吗啉
• 英文名称: 4-[(4-chloro-3-nitrophenyl)sulfonyl]morpholine
• 英文别名: 4-(4-chloro-3-nitro-benzenesulfonyl)-morpholine；4-(4-Chlor-3-nitro-benzolsulfonyl)-morpholin；4-[(4-chloro-3-nitrobenzene)sulfonyl]morpholine；4-(4-chloro-3-nitrophenyl)sulfonylmorpholine
• CAS: 22179-31-3
• 化学式: C₁₀H₁₁ClN₂O₅S
• mdl: MFCD00121800
• 分子量: 306.727
• InChiKey: ZWXQXPHBRFHIRB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  101
• 氢给体数：
  0
• 氢受体数：
  6

安全信息

• 海关编码：
  2934999090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-(4-Chloro-3-nitro-benzenesulfonyl)-morpholine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-(4-Chloro-3-nitro-benzenesulfonyl)-morpholine
CAS number: 22179-31-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H11ClN2O5S
Molecular weight: 306.7

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(4-氯-3-硝基苯磺酰基)-吗啉 在 tin(II) chloride dihdyrate 、 2-dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl 、 chloro(2-dicyclohexylphosphino-2′,6′-diisopropoxy-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) 、 caesium carbonate 作用下， 以 1,4-二氧六环 、 甲醇 、 乙醇 为溶剂， 反应 6.5h， 生成 (3R)-6-{[2-methoxy-5-(morpholin-4-ylsulfonyl)phenyl]amino}-1,3-dimethyl-4-(1-methylpiperidin-4-yl)-3,4-dihydropyrido[2,3-b]pyrazin-2(1H)-one
  参考文献：
  名称：

  BET蛋白抑制性的改性的二氢喹喔啉酮类化合物和二氢吡啶并吡嗪酮类化合物

  摘要：

  本发明涉及BET蛋白抑制性的、特别是BRD4-抑制性的通式(I)的二氢喹喔啉酮类化合物和二氢吡啶并吡嗪酮类化合物， 其中A、X、R 1 、R 2 、R 3 、R 4 、R 5 、R 6 和n具有在通式(I)中给出的含义，涉及用于制备本发明化合物的中间体，涉及包含根据本发明的化合物的药物组合物及其在过度增生性疾病、特别是肿瘤疾病中的预防和治疗用途。本发明还涉及BET蛋白抑制剂在病毒感染中、在神经变性疾病中、在炎性疾病中、在动脉粥样硬化性疾病中和在雄性生育控制中的用途。

  公开号：

  CN105518001A
• 作为产物：
  描述：

  吗啉 、 4-氯-3-硝基苯磺酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以24 g的产率得到4-(4-氯-3-硝基苯磺酰基)-吗啉
  参考文献：
  名称：

  BET蛋白抑制性的改性的二氢喹喔啉酮类化合物和二氢吡啶并吡嗪酮类化合物

  摘要：

  本发明涉及BET蛋白抑制性的、特别是BRD4-抑制性的通式(I)的二氢喹喔啉酮类化合物和二氢吡啶并吡嗪酮类化合物， 其中A、X、R 1 、R 2 、R 3 、R 4 、R 5 、R 6 和n具有在通式(I)中给出的含义，涉及用于制备本发明化合物的中间体，涉及包含根据本发明的化合物的药物组合物及其在过度增生性疾病、特别是肿瘤疾病中的预防和治疗用途。本发明还涉及BET蛋白抑制剂在病毒感染中、在神经变性疾病中、在炎性疾病中、在动脉粥样硬化性疾病中和在雄性生育控制中的用途。

  公开号：

  CN105518001A

文献信息

• [DE] ((11-OXO-10,11-DIHYDRODIBENZO [B, F] [1, 4] OXAZEPIN-1-YL)OXY) ESSIGSÄURE-DERIVATE UND VERWANDTE VERBINDUNGEN ALS HERZ-KREISLAUFMITTEL ZUR BEHANDLUNG VON ATHEROSCLEROSE<br/>[EN] ((11-OXO-10,11-DIHYDRODIBENZO [B, F] [1, 4] OXAZEPIN-1-YL)OXY) ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS AS CARDIOVASCULAR PREPARATIONS USED TO TREAT ARTERIOLOSCLEROSIS<br/>[FR] DERIVES D'ACIDE ((11-OXO-10,11-DIHYDRODIBENZO[B, F][1, 4]OXAZEPIN-1-YL)OXY) ACETIQUE ET COMPOSES APPARENTES COMME AGENTS CARDIOVASCULAIRES POUR LE TRAITEMENT DE L'ATHEROSCLEROSE
  申请人：BAYER HEALTHCARE AG

  公开号：WO2005072741A1

  公开（公告）日：2005-08-11

  Die vorliegende Erfindung betrifft Dibenzoxazepine und Verfahren zu ihrer Herstellung, ihre Verwendung zur Behandlung und/oder Prophylaxe von Krankheiten sowie ihre Verwendung zur Herstellung von Arzneimitteln zur Behandlung und/oder Prophylaxe von Krankheiten, insbesondere von Herz-Kreislauf-Erkrankungen, zB. von Atherosklerose, und Krebserkrankungen: Formel (I), worin R2 C1-C6-Alkyl bedeutet, wobei Alkyl substituiert sein kann mit 1 oder 2 Substituenten, wobei die Substituenten unabhängig voneinander ausgewählt werden aus der Gruppe bestehend aus Halogen, Hydroxy, Oxo, C1-C6-Alkoxy, Hydroxycarbonyl, C1-C6-Alkoxycarbonyl, Aminocarbonyl und C1-C6-Alkylaminocarbonyl, R3 -O-CH2CO2H oder -O-(CH2)2CO2H bedeutet, R5 5- bis 10-gliedriges Heteroaryl, -SO2-R6 oder -NR7(C=O)R8 bedeutet, wobei Heteroaryl substituiert sein kann mit 1, 2 oder 3 Substituenten, wobei die Substi­tuenten unabhängig voneinander ausgewählt werden aus der Gruppe bestehend aus Halogen, Trifluormethyl, Trifluormethoxy, Cyano, Nitro, Amino, C1-C6 Alkylamino, Hydroxy, C1-C6-Alkyl, C1-C6-AIkoxy, Hydroxycarbonyl, C1-C6-Alkoxycarbonyl, Amino­carbonyl, C1-C6-Alkylaminocarbonyl, C6-C10-Aryl und C3-C8-Cycloalkyl, die anderen Substituenten sind in den Ansprüchen definiert.

  本发明涉及二苯并噁唑和其制备方法，其用于治疗和/或预防疾病以及用于制备用于治疗和/或预防疾病的药物，特别是心血管疾病，例如动脉粥样硬化，和癌症的用途：式（I），其中R2为C1-C6烷基，其中烷基可以被1或2个取代基取代，取代基独立地选择自卤素、羟基、羰基、C1-C6烷氧基、羟基羰基、C1-C6烷氧羰基、氨基羰基和C1-C6烷基氨基羰基的群组，R3为-O-CH2CO2H或-O-(CH2)2CO2H，R5为5-至10-成员的杂环芳基，-SO2-R6或-NR7(C=O)R8，其中杂环芳基可以被1、2或3个取代基取代，取代基独立地选择自卤素、三氟甲基、三氟甲氧基、氰基、硝基、氨基、C1-C6烷基氨基、羟基、C1-C6烷基、C1-C6烷氧基、羟基羰基、C1-C6烷氧羰基、氨基羰基、C1-C6烷基氨基羰基、C6-C10芳基和C3-C8环烷基，其他取代基在权利要求中定义。
• New compounds
  申请人：——

  公开号：US20030149019A1

  公开（公告）日：2003-08-07

  The present invention relates to substituted bis-arylsulfonamide and arylsulfonamide compounds of the general formula (I) or the formula (II), which compounds are potentially useful for the prophylaxis and treatment of medical conditions relating to obesity, type II diabetes and/or disorders of the central nervous system. 1

  本发明涉及通式(I)或通式(II)的取代双芳基磺酰胺和芳基磺酰胺化合物，这些化合物可能对预防和治疗与肥胖、2型糖尿病和/或中枢神经系统紊乱相关的医疗状况有用。
• Benzene derivatives and pharmaceutical composition
  申请人：Kureha Chemical Industry Co., Ltd.

  公开号：US05696118A1

  公开（公告）日：1997-12-09

  A benzene derivative of the formula (I): ##STR1## wherein R.sup.1 is hydrogen, C.sub.1-6 -alkyl, C.sub.1-6 -haloalkyl, --NH.sub.2, --NHR.sup.21 ; R.sup.2 is hydroxyl, --OR.sup.22, three- to seven-membered saturated cycloaliphatic amino optionally interrupted by one or more nitrogen, oxygen or sulfur atoms, --NHR.sup.23, --N(R.sup.24).sub.2, --NH.sub.2 ; R.sup.4 is hydrogen, C.sub.1-6 -alkyl, or --C(.dbd.O)R.sup.25 ; R.sup.7 is --CO--, --SO.sub.2 --; R.sup.8 is --CO--, single bond; R.sup.12 is --R.sup.11 --R.sup.5 ; R.sup.11 is --N(R.sup.5)--, --NH--, --O--, --N(R.sup.26)--, --N(C(.dbd.O)R.sup.27)--, --N(C(.dbd.O)NH.sub.2)--, --N(C(.dbd.O)NHR.sup.28)--; R.sup.13 is hydrogen, C.sub.1-6 -alkyl, C.sub.1-6 -haloalkyl, --NHC(.dbd.O)(CH.sub.2).sub.m C.sub.6 H.sub.5, --NHC(.dbd.O)R.sup.29, --NHC(.dbd.O)CH(C.sub.6 H.sub.5).sub.2, --NH.sub.2, --NHR.sup.30, --(CH.sub.2).sub.n C.sub.6 H.sub.5 ; Z is C, CH, N; A is CH, N; R.sup.5 is hydrogen, --CH.sub.2 C.sub.6 H.sub.4 COOH, --CH.sub.2 C.sub.6 H.sub.4 COOR.sup.31, --CH.sub.2 C.sub.6 H.sub.4 OH, --CH.sub.2 C.sub.6 H.sub.4 OR.sup.32, --CH.sub.2 C.sub.6 H.sub.4 NH.sub.2, --CH.sub.2 C.sub.6 H.sub.4 N(R.sup.33).sub.2, --CH.sub.2 C.sub.6 H.sub.4 -azole, --CH.sub.2 C.sub.6 H.sub.4 NHR.sup.34, --CH.sub.2 C.sub.6 H.sub.4 C.sub.6 H.sub.4 R.sup.14 ; R.sup.14 is azole, --COOH; R.sup.21 to R.sup.34 are independently C.sub.1-6 -alkyl or C.sub.1-6 -haloalkyl; m is 0 to 6; n is 0 to 6; t is 0 or 1, with the proviso that when Z is N, R.sup.5 is hydrogen, --CH.sub.2 C.sub.6 H.sub.4 COOH, --CH.sub.2 C.sub.6 H.sub.4 COOR.sup.31, --CH.sub.2 C.sub.6 H.sub.4 OH, --CH.sub.2 C.sub.6 H.sub.4 OR.sup.32, --CH.sub.2 C.sub.6 H.sub.4 NH.sub.2, --CH.sub.2 C.sub.6 H.sub.4 N(R.sup.33).sub.2, --CH.sub.2 C.sub.6 H.sub.4 -azole, or --CH.sub.2 C.sub.6 H.sub.4 NHR.sup.34, or a salt thereof, and a pharmaceutical composition comprising said benzene derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier are disclosed.

  一种化学式为(I)的苯衍生物：其中R.sup.1是氢，C.sub.1-6-烷基，C.sub.1-6-卤代烷基，-NH.sub.2，-NHR.sup.21；R.sup.2是羟基，-OR.sup.22，三至七元饱和环脂肪族氨基，可选地由一个或多个氮、氧或硫原子中断，-NHR.sup.23，-N(R.sup.24).sub.2，-NH.sub.2；R.sup.4是氢，C.sub.1-6-烷基，或-C(.dbd.O)R.sup.25；R.sup.7是-CO-，-SO.sub.2-；R.sup.8是-CO-，单键；R.sup.12是-R.sup.11-R.sup.5；R.sup.11是-N(R.sup.5)-，-NH-，-O-，-N(R.sup.26)-，-N(C(.dbd.O)R.sup.27)-，-N(C(.dbd.O)NH.sub.2)-，-N(C(.dbd.O)NHR.sup.28)-；R.sup.13是氢，C.sub.1-6-烷基，C.sub.1-6-卤代烷基，-NHC(.dbd.O)(CH.sub.2).sub.mC.sub.6H.sub.5，-NHC(.dbd.O)R.sup.29，-NHC(.dbd.O)CH(C.sub.6H.sub.5).sub.2，-NH.sub.2，-NHR.sup.30，-(CH.sub.2).sub.nC.sub.6H.sub.5；Z是C，CH，N；A是CH，N；R.sup.5是氢，-CH.sub.2C.sub.6H.sub.4COOH，-CH.sub.2C.sub.6H.sub.4COOR.sup.31，-CH.sub.2C.sub.6H.sub.4OH，-CH.sub.2C.sub.6H.sub.4OR.sup.32，-CH.sub.2C.sub.6H.sub.4NH.sub.2，-CH.sub.2C.sub.6H.sub.4N(R.sup.33).sub.2，-CH.sub.2C.sub.6H.sub.4-唑，-CH.sub.2C.sub.6H.sub.4NHR.sup.34，-CH.sub.2C.sub.6H.sub.4C.sub.6H.sub.4R.sup.14；R.sup.14是唑，-COOH；R.sup.21到R.sup.34独立地是C.sub.1-6-烷基或C.sub.1-6-卤代烷基；m为0至6；n为0至6；t为0或1，但当Z为N时，R.sup.5是氢，-CH.sub.2C.sub.6H.sub.4COOH，-CH.sub.2C.sub.6H.sub.4COOR.sup.31，-CH.sub.2C.sub.6H.sub.4OH，-CH.sub.2C.sub.6H.sub.4OR.sup.32，-CH.sub.2C.sub.6H.sub.4NH.sub.2，-CH.sub.2C.sub.6H.sub.4N(R.sup.33).sub.2，-CH.sub.2C.sub.6H.sub.4-唑，或-CH.sub.2C.sub.6H.sub.4NHR.sup.34，或其盐，以及包括所述苯衍生物或其药学上可接受的盐的药物组合物和药学上可接受的载体。
• Synthesis and Photoluminescent Properties of 2-(3-Carboxymethylindazol-1-yl)anilines
  作者：A. A. Shetnev、V. A. Panova、P. M. Kutuzova、M. V. Tarasenko、M. V. Zhmykhova、S. V. Baykov、S. I. Filimonov

  DOI：10.1134/s1070363221060049

  日期：2021.6

  A two-stage method for the preparation of 2-(3-carboxymethylindazol-1-yl)anilines using the N-arylation reaction of 3-carboxymethylindazoles with o-nitrohaloarenes and subsequent reduction of nitro-containing intermediates with tin(II) chloride was developed. The experimental results showed that the use of the synthesized compounds as fluorophores in the visible region of the spectrum is promising.

  摘要 一种分两步制备 2-(3-羧甲基吲唑-1-基)苯胺的方法 采用 3-羧甲基吲唑与邻硝基卤代烯烃的 N-芳基化反应，然后用氯化锡（II）还原含硝基的中间产物，开发了一种分两步制备 2-(3-羧甲基吲唑-1-基)苯胺的方法。 开发出了利用 3-羧甲基吲唑与邻硝基卤代烯烃的 N-芳基化反应制备(3-羧甲基吲唑-1-基)苯胺并随后用氯化锡(II)还原含硝基中间体的方法。实验结果表明 实验结果表明，合成的化合物可用作 光谱可见区的荧光团。
• [EN] 3,4-DIAMINOBENZENESULFONAMIDE DERIVATIVES FOR INHIBITING CELL DEATH<br/>[FR] DÉRIVÉS DE 3,4-DIAMINOBENZÈNESULFONAMIDE POUR INHIBER LA MORT CELLULAIRE
  申请人：VIB VZW

  公开号：WO2016075330A1

  公开（公告）日：2016-05-19

  The present invention relates to a novel class of compounds having the structure of formula (I) and pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof. These compounds inhibit or reduce the non-apoptotic cell death forms ferroptosis and/or oxytosis rendering them useful for the treatment of various conditions disclosed herein.

  本发明涉及一种新型化合物类，其结构式为(I)，以及包含式(I)化合物或其药学上可接受的盐的制药组合物。这些化合物抑制或减少非凋亡细胞死亡形式的铁死亡和/或氧死亡，因此可用于治疗本文所披露的各种疾病。